 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Connective Portfolio Management LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD  Free Report) by 3.8% during the second quarter, according to the company in its most...

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Connective Portfolio Management LLC

Martin Capital Partners LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD  Free Report) by 1.7% during the 2nd quarter, Holdings Channel reports. The fund owned 40,997...

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Martin Capital Partners LLC

Procyon Advisors LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD  Free Report) by 71.9% during the 2nd quarter, according to its most recent filing with the...

Procyon Advisors LLC Has $1.34 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Venture Visionary Partners LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD  Free Report) by 3.8% during the second quarter, according to the company in its most recent 13F...

Venture Visionary Partners LLC Sells 295 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Pinnacle Bancorp Inc. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD  Free Report) by 115.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with...

Pinnacle Bancorp Inc. Has $149,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Franklin Street Advisors Inc. NC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD  Free Report) by 4.0% in the 2nd quarter, according to its most recent 13F filing with the...

Franklin Street Advisors Inc. NC Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Kite, a Gilead Company (Nasdaq: GILD), today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen...

Kites Car T-cell Therapy Yescarta Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma

Capital Investment Advisors LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD  Free Report) by 5.5% during the second quarter, according to the company in its most recent Form 13F...

Capital Investment Advisors LLC Has $23.54 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Unraveling Gilead Sciences Inc's Dividend Performance and Sustainability

Private Asset Management Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD  Free Report) by 14.4% during the second quarter, according to its most recent Form 13F...

Gilead Sciences, Inc. (NASDAQ:GILD) Stake Lessened by Private Asset Management Inc.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Watchers	75,926
52-Wk Low	$61.45
52-Wk High	$89.74

Market Cap	$93.24B
Volume (M)	3.89M
52-Wk High	$89.74
52-Wk Low	$61.45

GILD Gilead Sciences, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals